News Posts List
Japan's Takeda clinches $62 billion Shire deal as pharma M&A rolls on Source: Reuters Takeda Pharmaceutical agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion) on Tuesday, the biggest yet in a wave of deals sweeping the drugs industry. https://www.reuters.com/article/us-shire-m-a-takeda/japans-takeda-clinches-62-billion-shire-deal-as-pharma-ma-rolls-on-idUSKBN1I90IC Japan's biggest ever deal: Takeda buys Shire for $62 billion Source: CNN Japanese drugmaker Takeda has reached a $62 billion deal to buy rival Shire in the world's biggest takeover so far this year.
Seven Southeastern U.S. life science and medtech groups are joining forces to better promote and advocate for the region. The Southeastern Medical Device Association (SEMDA) on Wednesday announced the formation of an alliance with six individual state medtech and life science advocacy groups: BioAlabama, Bio Florida, Georgia Bio, ncbio, Life Science Tennessee and SCBIO. “Industry and academic partners simply cannot invest enough in each individual state’s bio advocacy organization — nor travel to each organization’s annual event every single year,” SEMDA executive director Jason Rupp said in a news release.
Halyard Health, Inc. announced the completion of the previously disclosed divestiture of its S&IP business to Owens and Minor, Inc. for $710 million, subject to certain adjustments as provided in the Amended and Restated Purchase Agreement. Halyard intends to use the approximately $600 million in net proceeds from the sale to pay off its existing Term Loan B credit facility and to fund internal investment and M&A. "The divestiture of S&IP transforms us into a focused, pure-play medical devices business with a clear playbook for solid revenue and earnings growth," said Joe Woody, Halyard chief executive officer. "The additional financial capacity will fund our dual-track growth strategy, focused on product innovation and strategic M&A and underpinned by a commitment to commercial excellence."
Alpharetta health-care tech company Reach Health was acquired telemedicine platform InTouch Health for an undisclosed amount, the companies announced April 30. Reach Health, whose platform fosters collaboration between bedside clinicians and remote specialists, has about 35 employees in Atlanta. Tim Wright, executive vice president of strategy and development at Santa Barbara, Calif.-based InTouch Health, said the Alpharetta office would remain in place. The telemedicine industry is rapidly consolidating, Saluke said. The acquisition will offer Reach Health's customers better support, security and compliance. InTouch will gain access to Reach's data driven approach to telemedicine, which brings down the cost of equipment.
ATLANTA—Georgia State has signed a licensing deal with Pinnacle Bio, a biotechnology firm that specializes in developing and marketing technologies to diagnose infectious diseases, to market a point-of-care influenza diagnostic developed by Suri Iyer, professor in the Department of Chemistry and the Center for Diagnostics & Therapeutics. Methods of diagnosing influenza are often expensive, not sensitive enough and require trained personnel to administer. Iyer and his colleagues have designed an accurate test that can detect influenza viruses in 15 minutes. The test requires only a nasal swab and detects a protein on the surface of the virus to identify influenza A and influenza B—the two main flu strains in humans. The research was funded by the National Institutes of Health.
ATLANTA—Vincent La Terza, assistant vice president and senior licensing agent at Georgia State University since 2017, has been named associate vice president of research and director of technology transfer and commercialization at Georgia State. He leads the university’s Office of Technology Licensing and Commercialization, which helps scientists bring their inventions and discoveries from the lab into the marketplace. La Terza, an attorney, is an experienced biopharma entrepreneur and has worked in technology transfer for the University of Georgia, Georgia Institute of Technology and Emory University, where he was the university’s first director of technology transfer.
The Manor Golf and Country Club to host May 8 event with proceeds benefiting STEM programming ATLANTA – April 17, 2018: Georgia Bio has announced that its 4th annual golf outing, Swings fore STEM, will be held on Tuesday, May 8, at The Manor Golf and Country Club in Milton, Ga. Georgia Bio is an organization that aims to grow Georgia’s leadership in life science innovation through support of entrepreneurship, science education and life science career development. Additionally, the Georgia BioEd Institute division strives to make a difference in the world of education by providing the tools and equipment teachers and students desperately need to succeed in STEM fields. This golf outing is part of the campaign to raise funds to promote and support all STEM education programs run by the Institute. The outing’s revenue will help to train teachers and maintain and stock the GaBioEd Equipment Depot which supplies teachers throughout Georgia with the tools needed to teach biology, chemistry, biotechnology, and other health sciences in the classrooms.
Hackathon winners develop innovative solutions for feeding pets, disease detection for backyard chickens and for supporting surgery and care of pets At the first-ever animal health-focused hackathon conducted in Georgia this past weekend, nearly 100 students applied inspiration and expertise spanning multiple disciplines to develop a number of potential solutions for the care and welfare of pets and livestock. Ideas ranging from a fitness tracker for owners and their pets to a thermo-detection drone for early identification of sick livestock were developed into four-minute pitches, many of which even featured prototypes developed over the course of the weekend. The grand prize-winning team, PetSense, developed an Alexa-compatible intelligent feeding and weight monitoring system for cats and dogs.
ATLANTA, GA / ACCESSWIRE / April 12, 2018 / NeurOp, Inc., a clinical-stage biotechnology company, today announced the initiation of a Phase 1 clinical trial of NP10679, a highly potent and selective GluN2B subunit-specific NMDA (N-methyl-D-aspartate) receptor inhibitor. NeurOp is investigating NP10679 for several neurological disorders that are associated with over-activity of these receptors. The randomized, placebo-controlled, single ascending dose study will assess the safety, pharmacokinetics and pharmacodynamics of NP10679 in healthy volunteers. The study is being conducted in collaboration with Pharmaron (Baltimore) and is currently enrolling subjects in the United States. Data collected from the study will inform dose and schedule for further development of NP10679 for potential use in severe pain and the prevention of ischemic damage following subarachnoid hemorrhage (SAH).
ATLANTA, April 6, 2018 – Vero Biotech is pleased to announce the opening of its new corporate headquarters in Georgia Tech’s Technology Enterprise Park on April 6, 2018. Vero Biotech, formerly GeNO LLC, is an emerging biotechnology company focused on the design, development, and commercialization of next generation inhaled Nitric Oxide (NO) delivery systems to address unmet needs of patients with cardiopulmonary conditions. “We are excited to be moving to Atlanta, where we will have access to a growing biotech community housed at Technology Enterprise Park, part of the Georgia Tech community; a highly skilled workforce; and an innovation support system that is essential for a startup company like Vero Biotech,” says Brent Furse, President and CEO of Vero Biotech. “It is significant for us to be able to work in an advanced new complex. The modern facility will enable us to continue to accommodate the growing needs of our research, development, and commercial opportunities.”
|Neon CRM by Neon One|